135 related articles for article (PubMed ID: 27882933)
1. Multiple myeloma risk variant at 7p15.3 creates an IRF4-binding site and interferes with CDCA7L expression.
Li N; Johnson DC; Weinhold N; Studd JB; Orlando G; Mirabella F; Mitchell JS; Meissner T; Kaiser M; Goldschmidt H; Hemminki K; Morgan GJ; Houlston RS
Nat Commun; 2016 Nov; 7():13656. PubMed ID: 27882933
[TBL] [Abstract][Full Text] [Related]
2. The 7p15.3 (rs4487645) association for multiple myeloma shows strong allele-specific regulation of the MYC-interacting gene CDCA7L in malignant plasma cells.
Weinhold N; Meissner T; Johnson DC; Seckinger A; Moreaux J; Försti A; Chen B; Nickel J; Chubb D; Rawstron AC; Doughty C; Dahir NB; Begum DB; Young K; Walker BA; Hoffmann P; Nöthen MM; Davies FE; Klein B; Goldschmidt H; Morgan GJ; Houlston RS; Hose D; Hemminki K
Haematologica; 2015 Mar; 100(3):e110-3. PubMed ID: 25480495
[No Abstract] [Full Text] [Related]
3. A Meta-analysis of Multiple Myeloma Risk Regions in African and European Ancestry Populations Identifies Putatively Functional Loci.
Rand KA; Song C; Dean E; Serie DJ; Curtin K; Sheng X; Hu D; Huff CA; Bernal-Mizrachi L; Tomasson MH; Ailawadhi S; Singhal S; Pawlish K; Peters ES; Bock CH; Stram A; Van Den Berg DJ; Edlund CK; Conti DV; Zimmerman T; Hwang AE; Huntsman S; Graff J; Nooka A; Kong Y; Pregja SL; Berndt SI; Blot WJ; Carpten J; Casey G; Chu L; Diver WR; Stevens VL; Lieber MR; Goodman PJ; Hennis AJ; Hsing AW; Mehta J; Kittles RA; Kolb S; Klein EA; Leske C; Murphy AB; Nemesure B; Neslund-Dudas C; Strom SS; Vij R; Rybicki BA; Stanford JL; Signorello LB; Witte JS; Ambrosone CB; Bhatti P; John EM; Bernstein L; Zheng W; Olshan AF; Hu JJ; Ziegler RG; Nyante SJ; Bandera EV; Birmann BM; Ingles SA; Press MF; Atanackovic D; Glenn MJ; Cannon-Albright LA; Jones B; Tricot G; Martin TG; Kumar SK; Wolf JL; Deming Halverson SL; Rothman N; Brooks-Wilson AR; Rajkumar SV; Kolonel LN; Chanock SJ; Slager SL; Severson RK; Janakiraman N; Terebelo HR; Brown EE; De Roos AJ; Mohrbacher AF; Colditz GA; Giles GG; Spinelli JJ; Chiu BC; Munshi NC; Anderson KC; Levy J; Zonder JA; Orlowski RZ; Lonial S; Camp NJ; Vachon CM; Ziv E; Stram DO; Hazelett DJ; Haiman CA; Cozen W
Cancer Epidemiol Biomarkers Prev; 2016 Dec; 25(12):1609-1618. PubMed ID: 27587788
[TBL] [Abstract][Full Text] [Related]
4. IRF4 addiction in multiple myeloma.
Shaffer AL; Emre NC; Lamy L; Ngo VN; Wright G; Xiao W; Powell J; Dave S; Yu X; Zhao H; Zeng Y; Chen B; Epstein J; Staudt LM
Nature; 2008 Jul; 454(7201):226-31. PubMed ID: 18568025
[TBL] [Abstract][Full Text] [Related]
5. C/EBPbeta regulates transcription factors critical for proliferation and survival of multiple myeloma cells.
Pal R; Janz M; Galson DL; Gries M; Li S; Jöhrens K; Anagnostopoulos I; Dörken B; Mapara MY; Borghesi L; Kardava L; Roodman GD; Milcarek C; Lentzsch S
Blood; 2009 Oct; 114(18):3890-8. PubMed ID: 19717648
[TBL] [Abstract][Full Text] [Related]
6. Allele-specific transcriptional regulation of IRF4 in melanocytes is mediated by chromatin looping of the intronic rs12203592 enhancer to the IRF4 promoter.
Visser M; Palstra RJ; Kayser M
Hum Mol Genet; 2015 May; 24(9):2649-61. PubMed ID: 25631878
[TBL] [Abstract][Full Text] [Related]
7. C-terminal binding protein 2 is a novel tumor suppressor targeting the MYC-IRF4 axis in multiple myeloma.
Cheung CHY; Cheng CK; Leung KT; Zhang C; Ho CY; Luo X; Kam AYF; Xia T; Wan TSK; Pitts HA; Chan NPH; Cheung JS; Wong RSM; Zhang XB; Ng MHL
Blood Adv; 2024 May; 8(9):2217-2234. PubMed ID: 38457926
[TBL] [Abstract][Full Text] [Related]
8. Genetic Predisposition to Multiple Myeloma at 5q15 Is Mediated by an ELL2 Enhancer Polymorphism.
Li N; Johnson DC; Weinhold N; Kimber S; Dobbins SE; Mitchell JS; Kinnersley B; Sud A; Law PJ; Orlando G; Scales M; Wardell CP; Försti A; Hoang PH; Went M; Holroyd A; Hariri F; Pastinen T; Meissner T; Goldschmidt H; Hemminki K; Morgan GJ; Kaiser M; Houlston RS
Cell Rep; 2017 Sep; 20(11):2556-2564. PubMed ID: 28903037
[TBL] [Abstract][Full Text] [Related]
9. MMSET regulates expression of IRF4 in t(4;14) myeloma and its silencing potentiates the effect of bortezomib.
Xie Z; Bi C; Chooi JY; Chan ZL; Mustafa N; Chng WJ
Leukemia; 2015 Dec; 29(12):2347-54. PubMed ID: 26196464
[TBL] [Abstract][Full Text] [Related]
10. Dissecting the impact of bromodomain inhibitors on the Interferon Regulatory Factor 4-MYC oncogenic axis in multiple myeloma.
Agnarelli A; Mitchell S; Caalim G; Wood CD; Milton-Harris L; Chevassut T; West MJ; Mancini EJ
Hematol Oncol; 2022 Aug; 40(3):417-429. PubMed ID: 35544413
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of bromodomain and extra-terminal (BET) proteins increases NKG2D ligand MICA expression and sensitivity to NK cell-mediated cytotoxicity in multiple myeloma cells: role of cMYC-IRF4-miR-125b interplay.
Abruzzese MP; Bilotta MT; Fionda C; Zingoni A; Soriani A; Vulpis E; Borrelli C; Zitti B; Petrucci MT; Ricciardi MR; Molfetta R; Paolini R; Santoni A; Cippitelli M
J Hematol Oncol; 2016 Dec; 9(1):134. PubMed ID: 27903272
[TBL] [Abstract][Full Text] [Related]
12. PU.1 acts as tumor suppressor for myeloma cells through direct transcriptional repression of IRF4.
Ueno N; Nishimura N; Ueno S; Endo S; Tatetsu H; Hirata S; Hata H; Matsuoka M; Mitsuya H; Okuno Y
Oncogene; 2017 Aug; 36(31):4481-4497. PubMed ID: 28368411
[TBL] [Abstract][Full Text] [Related]
13. A 16q22.1 variant confers susceptibility to colorectal cancer as a distal regulator of ZFP90.
Yu CY; Han JX; Zhang J; Jiang P; Shen C; Guo F; Tang J; Yan T; Tian X; Zhu X; Ma D; Hu Y; Xie Y; Du W; Zhong M; Chen J; Liu Q; Sun D; Chen Y; Zou W; Hong J; Chen H; Fang JY
Oncogene; 2020 Feb; 39(6):1347-1360. PubMed ID: 31641208
[TBL] [Abstract][Full Text] [Related]
14. Rate of CRL4(CRBN) substrate Ikaros and Aiolos degradation underlies differential activity of lenalidomide and pomalidomide in multiple myeloma cells by regulation of c-Myc and IRF4.
Bjorklund CC; Lu L; Kang J; Hagner PR; Havens CG; Amatangelo M; Wang M; Ren Y; Couto S; Breider M; Ning Y; Gandhi AK; Daniel TO; Chopra R; Klippel A; Thakurta AG
Blood Cancer J; 2015 Oct; 5(10):e354. PubMed ID: 26430725
[TBL] [Abstract][Full Text] [Related]
15. IRF4 in multiple myeloma-Biology, disease and therapeutic target.
Agnarelli A; Chevassut T; Mancini EJ
Leuk Res; 2018 Sep; 72():52-58. PubMed ID: 30098518
[TBL] [Abstract][Full Text] [Related]
16. Cereblon and IRF4 Variants Affect Risk and Response to Treatment in Multiple Myeloma.
Butrym A; Łacina P; Rybka J; Chaszczewska-Markowska M; Mazur G; Bogunia-Kubik K
Arch Immunol Ther Exp (Warsz); 2016 Dec; 64(Suppl 1):151-156. PubMed ID: 28083618
[TBL] [Abstract][Full Text] [Related]
17. Cancer: An unexpected addiction.
Shaughnessy JD
Nature; 2008 Jul; 454(7201):172-3. PubMed ID: 18615074
[No Abstract] [Full Text] [Related]
18. DOT1L inhibition blocks multiple myeloma cell proliferation by suppressing IRF4-MYC signaling.
Ishiguro K; Kitajima H; Niinuma T; Ishida T; Maruyama R; Ikeda H; Hayashi T; Sasaki H; Wakasugi H; Nishiyama K; Shindo T; Yamamoto E; Kai M; Sasaki Y; Tokino T; Nakase H; Suzuki H
Haematologica; 2019 Jan; 104(1):155-165. PubMed ID: 30171029
[TBL] [Abstract][Full Text] [Related]
19. Functional Analysis of a Novel Genome-Wide Association Study Signal in SMAD3 That Confers Protection From Coronary Artery Disease.
Turner AW; Martinuk A; Silva A; Lau P; Nikpay M; Eriksson P; Folkersen L; Perisic L; Hedin U; Soubeyrand S; McPherson R
Arterioscler Thromb Vasc Biol; 2016 May; 36(5):972-83. PubMed ID: 26966274
[TBL] [Abstract][Full Text] [Related]
20. Computational and functional characterization of four SNPs in the SOST locus associated with osteoporosis.
Ye W; Wang Y; Mei B; Hou S; Liu X; Wu G; Qin L; Zhao K; Huang Q
Bone; 2018 Mar; 108():132-144. PubMed ID: 29307778
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
